Jun 30, 2022 7:00am EDT Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
Jun 07, 2022 7:00am EDT Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
May 05, 2022 7:00am EDT Skye Bioscience Reports Enhanced Intraocular Pressure-Lowering of SBI-100 Formulation Published in Peer-Reviewed Journal
Apr 28, 2022 7:00am EDT Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
Mar 03, 2022 8:30am EST Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Feb 01, 2022 8:30am EST Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
Jan 10, 2022 7:00am EST Skye Bioscience Issues Shareholder Letter Providing Progress Update and Business Outlook for 2022
